WATCH LIVE
timothy sykes logo
RXRX Stock Gains Attention As ARK Investment Steps In Thumbnail
G Google News

RXRX Stock Gains Attention As ARK Investment Steps In

TIM SYKES•UPDATED JUN. 26, 2026, 11:33 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Recursion Pharmaceuticals Inc. stocks have been trading up by 7.34 percent after breakthrough AI-driven drug discovery partnership news.

Key Takeaways

  • Cathie Wood’s ARK Investment bought 260,000 RXRX shares, a fresh signal of institutional demand and growing interest from growth-focused funds.
  • The company is highlighted as a leading “full-stack” AI-first drug discovery platform, with automated data generation, machine-learning engines, pharma deals, and its own clinical pipeline.
  • Management granted inducement RSUs tied to about 3.0M Class A shares for 33 new hires, using stock to pull in talent while adding future dilution to the cap table.

Candlestick Chart

Live Update At 11:32:22 EDT: On Friday, June 26, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 7.34%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RXRX has been grinding higher over the past few weeks. From early 2026/06/01 around the mid-$3s, Recursion Pharmaceuticals has held that zone and recently pushed to a close near $3.59 on 2026/06/26. That’s not a parabolic squeeze, but it is a steady uptrend with higher lows, which traders like to see in a speculative biotech name.

Intraday on 2026/06/26, RXRX traded in a tight channel, climbing from the $3.30s out of the open toward the mid-$3.50s and holding its gains into midday. The 5‑minute chart shows controlled, stair-step buying rather than wild spreads, suggesting accumulative trading instead of pure day-trader churn.

More Breaking News

Fundamentally, RXRX is still a heavy cash-burn AI biotech. Revenue over the last year was about $74.7M, tiny compared to its enterprise value of roughly $1.19B, giving a rich price-to-sales multiple near 27. Profitability metrics are deep in the red, with operating margins heavily negative and free cash flow around -$81.4M last quarter. The flip side: RXRX carries minimal debt, a current ratio of 5.5, and roughly $654M in cash and equivalents, giving the company a runway to keep funding that AI-first drug discovery push.

Why Traders Are Watching RXRX Momentum

RXRX is back on screens mainly because of one thing: ARK Investment just bought size. Cathie Wood’s ARK picked up 260,000 shares according to the latest news on 2026/06/24, and that kind of institutional buy tends to wake up traders. When a high-profile, growth-focused fund leans into a story stock like Recursion Pharmaceuticals, short sellers and momentum players both take notice.

The ARK purchase lines up with what RXRX is trying to sell the market: a “full‑stack” AI-first drug discovery platform. Recursion Pharmaceuticals isn’t just a tiny lab with one drug in phase 1. The company is described as one of the largest, best-known AI-first players in the space, running massive automated biological experiments, feeding that data into machine-learning models, then pushing the best candidates into its own clinical pipeline and through big-pharma partnerships. For traders who chase AI narratives, RXRX blends hot tech buzz with biotech optionality.

That story helps explain why RXRX can hold a high price-to-sales multiple despite brutal negative margins. The market is paying for the platform and the data, not the current income statement. At the same time, Recursion Pharmaceuticals is hiring aggressively, granting inducement RSUs tied to about 3.0M Class A shares for 33 new employees under its 2024 Inducement Equity Incentive Plan. For traders, that screams “growth mode” but also flags ongoing dilution risk. RXRX is clearly betting that loading up on talent and scaling its AI engine will matter more than near-term earnings, a typical stance in high-growth biotech and AI names.

Conclusion

For active traders, RXRX sits at the crossroads of two powerful themes: AI and biotech. Recursion Pharmaceuticals has real scale in automated biology and machine learning, deep pharma collaborations, and a fully integrated pipeline, and that’s exactly the kind of long-term disruption narrative that attracts funds like ARK Investment. The recent 260,000‑share ARK buy adds a tangible catalyst to the story, reinforcing the gradual price strength we’ve seen on the RXRX chart in June.

But the numbers remind us what RXRX really is right now: a cash-burning science project with big ambitions and a big war chest. Margins are deeply negative, free cash flow is sharply below zero, and management continues to lean on stock-based pay, including the new inducement RSUs for 33 hires. That combination brings both upside optionality and real dilution risk.

This is why disciplined traders treat RXRX as a trading vehicle, not a set‑and‑forget holding. As Tim Sykes loves to say, “Trade the price action, not the hype.” As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. If RXRX keeps attracting smart-money buyers and holding higher lows, momentum traders will stay interested. If the story fades and support breaks, you cut losses fast and move on. Either way, RXRX is a name to study, not blindly trust, in this AI‑driven biotech wave.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”